News
Genzyme’s Most Recent News
inv_genz_news Genzyme General News
| November 18, 2009 |
Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder | | November 17, 2009 |
Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA | | November 16, 2009 |
Genzyme Receives Complete Response Letter on Lumizyme Application | | November 13, 2009 |
Genzyme Issues Letters to U.S. Healthcare Providers | | October 21, 2009 |
Genzyme Reports Third-Quarter Financial Results | | October 20, 2009 |
First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease | | October 14, 2009 |
Scientists Name Genzyme a Top Employer | | October 6, 2009 |
Genzyme Receives FDA Complete Response Letter for Clolar | | October 2, 2009 |
Genzyme Named to Dow Jones Sustainability World and North American Indexes | | September 24, 2009 |
Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia |
Genzyme News—One Year Archive >
Genzyme Financial News >
|
|
|
|
CONTACT INFORMATION: |
|
Genzyme Investor Relations
500 Kendall Street
Cambridge, MA 02142
T: 617 252 7500
Patrick Flanigan – 617 768 6563
Investor Information Line
U.S. T: 800 905 4369
Outside the U.S. T: 678 999 4572
Shareholder Contact
For questions about your shares, replacement of a lost stock certificate or a change of address call our transfer agent.
American Stock Transfer
59 Maiden Lane
New York, NY 10038
T: 212 936 5100
or
Genzyme Shareholder Services
T: 617 768 6686
|
|
|
|
Home
